Evidence map›Paper›PMID 34085418›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.

Jia Li, Meng Zheng, Olga Shimoni, William A Banks, Ashley I Bush, Jennifer R Gamble, Bingyang Shi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Peptide-functionalized nanoparticles for brain-targeted therapeutics.Drug delivery and translational research · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. A Review on the Pathophysiology of Alzheimer's Disease.Current protein & peptide science · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Jia LiSchool of Pharmacy, Henan University, Kaifeng, 475001, China.
Meng ZhengHenan-Macquarie University Joint Center for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China.
Olga ShimoniInstitute for Biomedical Materials and Devices, School of Mathematical and Physical Sciences, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, 2007, Australia.
William A BanksGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System and Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98108, USA.
Ashley I BushMelbourne Dementia Research Center, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, 3052, Australia.
Jennifer R GambleCenter for the Endothelium, Vascular Biology Program, Centenary Institute, The University of Sydney, Sydney, New South Wales, 2042, Australia.
Bingyang ShiSchool of Pharmacy, Henan University, Kaifeng, 475001, China.ORCID 0000-0002-1043-3163
Henan University · CNThe University of Melbourne · AUThe University of Sydney · AUUniversity of Puget Sound · USUniversity of Technology Sydney · AU

Funding

National Health and Medical Research Council GNT1166024National Health and Medical Research Council GNT1183057National Health and Medical Research Council GNT1194825National Key Technologies R&D program of China 2018YFA0209800National Natural Science Foundation of China 31640027New South Wales Health
6 · The paper itself

Abstract

The blood-brain barrier (BBB) is a highly specialized neurovascular unit, initially described as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from entering the brain. An intact BBB is also critical for the maintenance of normal neuronal function. In cerebral vascular diseases and neurological disorders, the BBB can be disrupted, contributing to disease progression. While restoration of BBB integrity serves as a robust biomarker of better clinical outcomes, the restrictive nature of the intact BBB presents a major hurdle for delivery of therapeutics into the brain. Recent studies show that the BBB is actively engaged in crosstalk between neuronal and the circulatory systems, which defines another important role of the BBB: as an interfacing conduit that mediates communication between two sides of the BBB. This role has been subject to extensive investigation for brain-targeted drug delivery and shows promising results. The dual roles of the BBB make it a unique target for drug development. Here, recent developments and novel strategies to target the BBB for therapeutic purposes are reviewed, from both barrier and carrier perspectives.

Indexed as

AnimalsBiological TransportBlood-Brain BarrierDrug CarriersDrug Delivery SystemsHumansMiceNanoparticle Drug Delivery SystemDrug CarriersNanoparticle Drug Delivery Systemblood-brain barrierbrain diseasesdrug deliverynanomedicinenanotechnology

Identifiers

PMID34085418
PMCPMC8373165
OpenAlexW3165847087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.